|
|
|
|
| LEADER |
04504nmm a2200337 u 4500 |
| 001 |
EB000672413 |
| 003 |
EBX01000000000000000525495 |
| 005 |
00000000000000.0 |
| 007 |
cr||||||||||||||||||||| |
| 008 |
140122 ||| eng |
| 020 |
|
|
|a 9783642740541
|
| 245 |
0 |
0 |
|a Pharmacology of the Skin II
|h Elektronische Ressource
|b Methods, Absorption, Metabolism and Toxicity, Drugs and Diseases
|
| 250 |
|
|
|a 1st ed. 1989
|
| 260 |
|
|
|a Berlin, Heidelberg
|b Springer Berlin Heidelberg
|c 1989, 1989
|
| 300 |
|
|
|a XXXVII, 587 p
|b online resource
|
| 505 |
0 |
|
|a Section A: Methods -- 1 Methods for the Study of Proliferative Rates in Epidermis -- 2 Tissue and Fluids: Sampling Techniques -- 3 Measurement of Sweating and Sweat Gland Function -- 4 Measurement of Human Sebaceous Gland Function -- 5 Methods for Assessing the Effect of Drugs on Hair and Nails -- 6 Measurement of Drug Action in the Skin: Sensation -- 7 The Measurement of Itch -- 8 Measurement of Skin Thickness, Wealing, Irritant, Immune and Ultraviolet Inflammatory Response in Skin -- 9 Measurement of Drug Action in Skin: Dermal Connective Tissue -- 10 Microbiological Sampling Techniques -- 11 Clinical Trial Methods -- Section B: Absorption, Metabolism and Toxicity -- 12 The Properties of Skin as a Diffusion Barrier and Route for Absorption -- 13 Skin as a Mode for Systemic Drug Administration -- 14 Drug Metabolism in the Skin -- 15 Skin Cancer (Excluding Melanomas) -- 16 Toxicology of Cosmetics -- 17 Drug Sensitisation -- Section C: Drugs and Diseases -- 18 H1- and H2-Receptor Antagonists -- 19 Clinical Pharmacology of Topical Steroids -- 20 Glucocorticoids and Lipocortin -- 21 Cutaneous Vasodilators -- 22 Fibrinolysis and Fibrinolytic Drugs -- 23 Non-steroidal Anti-inflammatory Agents and the Skin -- 24 Immunosuppressive (Cytotoxic) and Immunostimulant Drugs -- 25 Three Generations of Retinoids: Basic Pharmacologic Data, Mode of Action, and Effect on Keratinocyte Proliferation and Differentiation -- 26 Hypolipidaemic Agents in the Treatment of Xanthomata -- 27 Drugs Acting on Dermal Connective Tissue -- 28 Fungal Skin Infections -- 29 Bacterial Infections -- 30 Herpes Virus Infections -- 31 The Urticarias -- 32 Eczema -- 33 Treatment of Psoriasis -- 34 Anthralin -- 35 The Treatment of Acne -- 36 Pharmacology of Anti-androgens in the Skin -- 37 The Effect of Drugs on Hair -- 38 Photochemotherapy -- 39 Dapsone and Sulphapyridine -- 40 Zinc Deficiency -- 41 The Ichthyoses -- 42 Tropical Skin Diseases
|
| 653 |
|
|
|a Human Physiology
|
| 653 |
|
|
|a Pharmacy
|
| 653 |
|
|
|a Human physiology
|
| 653 |
|
|
|a Family medicine
|
| 653 |
|
|
|a Pharmacology
|
| 653 |
|
|
|a Dermatology
|
| 653 |
|
|
|a General Practice and Family Medicine
|
| 710 |
2 |
|
|a SpringerLink (Online service)
|
| 041 |
0 |
7 |
|a eng
|2 ISO 639-2
|
| 989 |
|
|
|b SBA
|a Springer Book Archives -2004
|
| 490 |
0 |
|
|a Handbook of Experimental Pharmacology
|
| 028 |
5 |
0 |
|a 10.1007/978-3-642-74054-1
|
| 856 |
4 |
0 |
|u https://doi.org/10.1007/978-3-642-74054-1?nosfx=y
|x Verlag
|3 Volltext
|
| 082 |
0 |
|
|a 615
|
| 520 |
|
|
|a The recent interest in the pharmacology of the skin and the treatment of its diseases has come about for two reasons. The first is a realisation that many aspects of pharmacology can be studied as easily in human skin as in animal models, where they may be more relevant to human physiology and disease. Examples of this are the action of various vasoactive agents and the isolation of mediators of inflammation after UV irradiation and antigen-induced dermatitis. The second reason is the fortuitous realisation that a pharmacological approach to the treatment of skin disease need not always await the full elucidation of aetiology and mechanism. For example, whilst the argument continued un resolved as to whether the pilo-sebaceous infection which constitutes acne was due to a blocked duct or to a simple increase in sebum production, 13-cis retinoic acid, was found quite by chance totally to ablate the disease; again, whilst cyclosporin, fresh from its triumphs in organ transplantation, has been found able to suppress the rash of psoriasis, it has resuscitated the debate on aetiology. We are therefore entering a new era in which the pharmacology and clinical pharmacology of skin are being studied as a fascinating new way of exploring questions of human physiology and pharmacology as well as for the development and study of new drugs, use of which will improve disease control and at the same time help to define pathological mechanisms
|